Risk factors

Maze Therapeutics (MAZE) risk factors

Item 1A of every Maze Therapeutics, Inc. 10-K on file, and what changed from one year to the next.

Open MAZE in Gloomberb →
  • FY2025 10-K risk factors

    90 risks, 4 new, 2 dropped, 11 reworded since the prior year. Maze Therapeutics added significant debt obligations through a new $200.0 million credit facility with Hercules Capital. The company highlighted increased financing activities, including private placements of common stock and pre-funded warrants.

    Filed Mar 25, 2026
  • FY2024 10-K risk factors

    88 risks. Maze Therapeutics relies heavily on early-stage drug candidates, specifically lead program MZE829, and its Compass platform for genetic target discovery. The company faces significant financial, clinical, and regulatory hurdles, including third-party dependencies for data, manufacturing, and clinical trials.

    Filed Mar 31, 2025